Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19 13206442-13623990 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258 Supported Approved Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 18.1 stomach: 6.4 CACNA1B CACNL1A5, CACNN, Cav2.2 ENSG00000148408 Calcium channel, voltage-dependent, N type, alpha 1B subunit 9 137877789-138124624 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA044347 Uncertain Tissue enhanced Group enriched 8 adrenal gland: 3.7;cerebral cortex: 14.9;fallopian tube: 4.8;testis: 7.6 prostate: 1.0 CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium channel, voltage-dependent, L type, alpha 1C subunit 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796 Supported Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium channel, voltage-dependent, L type, alpha 1D subunit 3 53494656-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.7 CACNA1E BII, CACH6, CACNL1A6, Cav2.3 ENSG00000198216 Calcium channel, voltage-dependent, R type, alpha 1E subunit 1 181413102-181808084 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA042515 Approved Plasma membrane
Actin filaments
Cytosol Mixed Tissue enriched 7 cerebral cortex: 10.3 adrenal gland: 1.3 CACNA1F AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2 ENSG00000102001 Calcium channel, voltage-dependent, L type, alpha 1F subunit X 49205063-49233371 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Not detected Mixed lymph node: 1.6 CACNA1G Cav3.1, NBR13 ENSG00000006283 Calcium channel, voltage-dependent, T type, alpha 1G subunit 17 50561068-50627474 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA004714 Uncertain Mixed Tissue enhanced cerebral cortex: 10.6;cervix, uterine: 8.5 endometrium: 5.2 CACNA1H Cav3.2 ENSG00000196557 Calcium channel, voltage-dependent, T type, alpha 1H subunit 16 1153241-1221771 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039125 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable) Expressed in all Tissue enhanced ovary: 50.6 seminal vesicle: 46.9 CACNA1I Cav3.3 ENSG00000100346 Calcium channel, voltage-dependent, T type, alpha 1I subunit 22 39570753-39689737 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 4.7;thyroid gland: 2.7 adrenal gland: 2.3 CACNA1S CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5 ENSG00000081248 Calcium channel, voltage-dependent, L type, alpha 1S subunit 1 201039512-201112566 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB009507, HPA048892, HPA056815 Supported Tissue enhanced Tissue enriched 34 skeletal muscle: 103.0 esophagus: 3.0